Over 90% of children in the world with special types of blood cancers called lymphomas are from sub-Saharan Africa.

This is because a virus called Epstein-Barr virus (EBV), malaria and HIV all contribute to causing these specific types of lymphomas.
Their treatment is widely available and free-of-charge in most sub-Saharan countries. However, currently, most children either remain undiagnosed, present late to hospital, or are diagnosed late while in hospital. One of the main reasons for this is the lack of reliable hospital-based diagnostics services with enough surgeons and pathologists to establish the precise diagnosis fast enough.

Research

Research


Analysis

Analysis


Diagnosis

Diagnosis

S

Treatment

Treatment


Professor Anna SchuhMD, PhD, FRCP, FRCPath, Honorary Consultant Haematologist, University of Oxford, UK

Professor Anna Schuh
MD, PhD, FRCP, FRCPath, Honorary Consultant Haematologist, University of Oxford, UK

Professor Anna Schuh completed academic and clinical haematology training in Oxford in 2006. Since then, she has been a principal investigator for over 30 early and late phase practice-changing clinical trials in chronic lymphocytic leukaemia. Her laboratory research has been with the evaluation of precision diagnostics tools for patients with cancer, in particular whole genome sequencing. In the past three years, her group has focussed on the analysis of liquid biopsies for early cancer diagnosis and monitoring of minimal residual disease. She is the director of an online part-time Precision Cancer Medicine Master's program and has published over 280 peer-reviewed publications. She receives grant funding from NIHR, CRUK, Welcome Trust, Innovate UK and various industry partners.    . 

Read More

Sam M. Mbulaiteye, MBChB, M.Phil., M.Med., of the DCEG Infections and Immunoepidemiology Branch (IIB), presented an NIH Director's Seminar titled "Burkitt Lymphoma: A Model of Polymicrobial Carcinogenesis and Global Oncology", and discussed his ideas for future research collaboration.

CPI is a new, commercially sustainable social enterprise which focuses on curing the curable through precise DNA-based diagnosis that will prevent the needless deaths of thousands of children in Sub-Saharan Africa (SSA).

SEREN is a new, commercially sustainable social enterprise which focuses on curing the curable through precise DNA-based diagnosis that will prevent the needless deaths of thousands of children in Sub-Saharan Africa (SSA).